Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database
-
Published:2021-12
Issue:
Volume:60
Page:138-146
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
Annonay MylèneORCID, Gauquelin Lisa, Geiss Romain, Ung Mony, Cristol-Dalstein Laurence, Mouret-Reynier Marie-Ange, Goncalves Anthony, Abadie-Lacourtoisie Sophie, Francois Eric, Perrin Christophe, Le Fel Johan, Lorgis Véronique, Servent Véronique, Uwer Lionel, Jouannaud Christelle, Leheurteur Marianne, Joly Florence, Campion Loic, Courtinard Coralie, Villacroux Olivier, Petit Thierry, Soubeyran PierreORCID, Terret Catherine, Bellera CarineORCID, Brain EtienneORCID, Delaloge SuzetteORCID
Funder
Eisai Roche Meso Scale Diagnostics Pfizer AstraZeneca Daiichi-Sankyo
Subject
General Medicine,Surgery
Reference31 articles.
1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;Ferlay;Int J Cancer,2019 2. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016;Deluche;Eur J Canc avr,2020 3. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women;Jenkins;Oncol,2014 4. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med. 15 mars,2001 5. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study;Swain;Lancet Oncol avr,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|